Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO

Opinion
Video

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Recent Videos
Marion Munk, MD, PhD, presenting slides
Related Content
Opthea to present at upcoming events to highlight work on wet AMD

Opthea to present at upcoming events to highlight work on wet AMD

Sydney M Crago
November 21st 2024
Article
AlloVir, Inc. enters definitive merger agreement to combine with Kalaris Therapeutics

AlloVir, Inc. enters definitive merger agreement to combine with Kalaris Therapeutics

Sydney M Crago
November 18th 2024
Article
Wet AMD therapeutics: Technologies raising the ceiling for functional visual outcomes

Wet AMD therapeutics: Technologies raising the ceiling for functional visual outcomes

Sean D. Adrean, MD, FAAO
November 14th 2024
Article
FDA authorizes marketing of Valeda Light Delivery System for treatment of patients with dry AMD

FDA authorizes marketing of Valeda Light Delivery System for treatment of patients with dry AMD

Sydney M Crago
November 12th 2024
Article
FDA clears investigational new drug (IND) application for HG202 by HuidaGene Therapeutics

FDA clears investigational new drug (IND) application for HG202 by HuidaGene Therapeutics

Sydney M Crago
November 12th 2024
Article
Noninvasive choroidal vessel analysis using deep learning: A novel approach to OCT angiography

Noninvasive choroidal vessel analysis using deep learning: A novel approach to OCT angiography

David Hutton
November 11th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.